EPS: As of FY2025 Q1, the actual value is USD -0.06.

Segment Revenue

• The company did not generate any operating revenues for the three months ended March 31, 2025, as it is a blank check company focused on finding a business combination.

Operational Metrics

• Net Loss: The company reported a net loss of $363,640 for the three months ended March 31, 2025, compared to a net loss of $1,238,211 for the same period in 2024.
• General and Administrative Expenses: These expenses were $191,850 for the three months ended March 31, 2025, down from $510,056 in the same period in 2024.
• Change in Fair Value of Derivative Liabilities: The company recorded a gain of $187,430 from the change in fair value of derivative liabilities for the three months ended March 31, 2025, compared to a loss of $990,040 in the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: The company used $72,033 in net cash for operating activities for the three months ended March 31, 2025, compared to $149,102 in the same period in 2024.
• Net Cash Used in Financing Activities: The company used $26,328 in net cash for financing activities for the three months ended March 31, 2025, compared to $34,357,416 in the same period in 2024.

Unique Metrics

• Investments Held in Trust Account: The balance of investments held in the trust account was $5,354,147 as of March 31, 2025, compared to $5,285,060 as of December 31, 2024.

Future Outlook and Strategy

• Core Business Focus: The company has until November 15, 2025, to consummate an initial business combination. If not completed by this date, the company must cease operations, redeem public shares, and liquidate.
• Non-Core Business: The company terminated its business combination agreement with Phytanix Bio on April 7, 2025, and is seeking other potential business combinations.